Logo
Unionpedia
Communication
Get it on Google Play
New! Download Unionpedia on your Android™ device!
Free
Faster access than browser!
 

Postmarketing surveillance and Rimonabant

Shortcuts: Differences, Similarities, Jaccard Similarity Coefficient, References.

Difference between Postmarketing surveillance and Rimonabant

Postmarketing surveillance vs. Rimonabant

Postmarketing surveillance (PMS) (also post market surveillance) is the practice of monitoring the safety of a pharmaceutical drug or medical device after it has been released on the market and is an important part of the science of pharmacovigilance. Rimonabant (also known as SR141716; trade names Acomplia, Zimulti) is an anorectic antiobesity drug that was first approved in Europe in 2006 but was withdrawn worldwide in 2008 due to serious psychiatric side effects; it was never approved in the United States.

Similarities between Postmarketing surveillance and Rimonabant

Postmarketing surveillance and Rimonabant have 1 thing in common (in Unionpedia): Food and Drug Administration.

Food and Drug Administration

The Food and Drug Administration (FDA or USFDA) is a federal agency of the United States Department of Health and Human Services, one of the United States federal executive departments.

Food and Drug Administration and Postmarketing surveillance · Food and Drug Administration and Rimonabant · See more »

The list above answers the following questions

Postmarketing surveillance and Rimonabant Comparison

Postmarketing surveillance has 18 relations, while Rimonabant has 22. As they have in common 1, the Jaccard index is 2.50% = 1 / (18 + 22).

References

This article shows the relationship between Postmarketing surveillance and Rimonabant. To access each article from which the information was extracted, please visit:

Hey! We are on Facebook now! »